Personalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Your Basket's Financial Footprint
Aggregate market capitalisation and investor takeaways for the provided basket.
- Large-cap dominance generally implies lower volatility and closer broad-market tracking, reducing idiosyncratic risk.
- Suitable as a core, long-term holding for diversification rather than a short-term speculative position.
- Expect steady, long-term value creation rather than rapid, short-term gains; growth may be more measured.
PSNL: $848.64M
PRME: $977.47M
EDIT: $348.89M
- Other
About This Group of Stocks
Our Expert Thinking
The healthcare industry is shifting from one-size-fits-all treatments to therapies designed for specific genetic profiles. Companies in this collection are pioneering technologies that target diseases at their molecular source, potentially offering more effective treatments with fewer side effects.
What You Need to Know
This portfolio includes companies at various stages of innovation—from diagnostic tools to therapeutic development. Consider this an aggressive growth component for your investments, as many firms are still developing commercial pathways for their technologies.
Why These Stocks
These companies were selected for their leadership in genomic sequencing, biomarker discovery, and targeted therapies like CRISPR gene editing. Recent regulatory approvals for gene-specific treatments and AI advancements in drug discovery provide significant growth catalysts.
Why You'll Want to Watch These Stocks
The DNA of Future Medicine
Personalized medicine is rewriting healthcare's rulebook. These companies are at the forefront of a revolution that could make traditional treatments obsolete while creating entirely new markets.
Breakthrough Momentum
Recent regulatory approvals for gene therapies are accelerating the path to market. As more personalized treatments gain validation, these pioneering companies could see rapid adoption and growth.
Beyond One-Size-Fits-All
Imagine treatments designed specifically for your genetic code. These companies are making this a reality, potentially capturing massive value as healthcare shifts toward precision therapies with better outcomes.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
India E-Commerce Beyond Amazon's $35B Investment
Amazon is investing $35 billion in India to expand its e-commerce and AI capabilities, signaling immense confidence in the nation's digital economy. This creates a ripple effect, boosting opportunities for companies in logistics, digital payments, and local technology sectors that support this large-scale economic transformation.
Retail Restructuring Explained: PepsiCo Cost-Cutting
Following an agreement with an activist investor, PepsiCo is launching a major cost-cutting initiative that includes slashing its product line and lowering prices. This strategic overhaul creates opportunities for companies specializing in supply chain automation and logistics, as well as for discount retailers who can capitalize on the shifting consumer landscape.
Digital Identity Stocks May Rise in 2025
Australia's pioneering law banning social media for users under 16 creates a new, mandatory market for online age verification. This theme focuses on companies providing the essential digital identity and safety technologies that platforms now need to comply with this and future global regulations.